Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-Three Hi
- Development stage
- Unknown
- Lead developer
- TOA Biopharma
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BIO-THREE Hi錠 (Bio-Three Hi Tablets) is an oral probiotic formulation developed by TOA Biopharma and distributed by Alinamin Pharmaceutical. It is classified as a designated quasi-drug in Japan and is indicated for the regulation of intestinal flora, relief of constipation, loose stools, and abdominal bloating. The formulation contains three symbiotic active bacterial strains: Clostridium butyricum TO-A (butyric acid bacteria), Enterococcus faecalis T-110 (lactic acid bacteria), and Bacillus mesentericus TO-A (saccharifying bacteria). These three strains work synergistically throughout the small and large intestines to promote the growth of beneficial bacteria (such as Bifidobacterium), inhibit pathogenic bacteria, and produce butyric acid and lactic acid to support the intestinal barrier and maintain gastrointestinal homeostasis.
- Brand names
- BIO-THREE HiBIO-THREE Hi TabletsBIO-THREE Hi tabletBIO-THREE Hi錠Bioslee HiBiosuri HiビオスリーHi錠
- Other names
- Bacillus mesentericus + Clostridium butyricum + Enterococcus faecalisBacillus subtilis + Clostridium butyricum + Enterococcus faecalisbutyric acid bacteria + lactic acid bacteria + saccharifying bacteria
Beyond the preview
Go deeper on Bio-Three Hi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Three Hi.